[S-8] 8x8, Inc. Employee Benefit Plan Registration
Q2-25 headline: Net revenue $150.0 M (+72% YoY) driven by Auvelity, Sunosi and first weeks of Symbravo launch; GAAP net loss narrowed to $48.0 M (-39% YoY) or 鈥�$0.97/sh.
Six-month revenue reached $271.5 M (+67%) while loss trimmed to $107.4 M. Gross margin remained high (cost of revenue 鈮�9% of sales), but SG&A climbed 26% to $130.3 M as Axsome expanded its commercial footprint. R&D held steady at $49.5 M with multiple late-stage CNS programs in progress.
Cash & equivalents closed at $303.0 M; operating cash burn fell to $75.8 M. In May the company refinanced via a new $570 M facility with Blackstone: $120 M term loan and $70 M revolver drawn, retiring the costlier Hercules loan and expected to lower interest expense; Blackstone also invested $15 M in common stock. Total debt now $188 M, shareholders鈥� equity $73 M.
FDA approved migraine therapy Symbravo in Jan-25 with U.S. launch in June, giving Axsome three commercial products. Management believes current liquidity funds operations for at least 12 months. Key risks are sustained commercial uptake, sizable rebates/discounts ($118 M accrued), and ongoing operating losses.
Titolo Q2-25: Ricavi netti di 150,0 milioni di dollari (+72% su base annua) trainati da Auvelity, Sunosi e dalle prime settimane del lancio di Symbravo; la perdita netta GAAP si 猫 ridotta a 48,0 milioni di dollari (-39% su base annua) ovvero -0,97 dollari per azione.
I ricavi semestrali hanno raggiunto 271,5 milioni di dollari (+67%) mentre la perdita si 猫 ridotta a 107,4 milioni. Il margine lordo 猫 rimasto elevato (costo del venduto 鈮�9% delle vendite), ma le spese SG&A sono aumentate del 26% a 130,3 milioni, in seguito all'espansione della presenza commerciale di Axsome. La R&S 猫 rimasta stabile a 49,5 milioni con diversi programmi CNS in fase avanzata in corso.
La liquidit脿 e equivalenti si sono attestati a 303,0 milioni; il consumo di cassa operativo 猫 sceso a 75,8 milioni. A maggio la societ脿 ha rifinanziato tramite una nuova linea da 570 milioni con Blackstone: un prestito a termine da 120 milioni e una linea revolving da 70 milioni utilizzata, estinguendo il pi霉 costoso prestito Hercules e prevedendo una riduzione delle spese per interessi; Blackstone ha inoltre investito 15 milioni in azioni ordinarie. Il debito totale 猫 ora di 188 milioni, il patrimonio netto degli azionisti di 73 milioni.
La FDA ha approvato a gennaio 2025 la terapia per l'emicrania Symbravo, con lancio negli Stati Uniti a giugno, portando a tre i prodotti commerciali di Axsome. La direzione ritiene che la liquidit脿 attuale copra le operazioni per almeno 12 mesi. I rischi principali sono il mantenimento delle vendite commerciali, significativi rimborsi/sconti accumulati (118 milioni) e le perdite operative in corso.
Titular Q2-25: Ingresos netos de 150,0 millones de d贸lares (+72% interanual) impulsados por Auvelity, Sunosi y las primeras semanas del lanzamiento de Symbravo; la p茅rdida neta GAAP se redujo a 48,0 millones de d贸lares (-39% interanual) o -0,97 d贸lares por acci贸n.
Los ingresos a seis meses alcanzaron 271,5 millones (+67%), mientras que la p茅rdida se redujo a 107,4 millones. El margen bruto se mantuvo alto (costo de ventas 鈮�9% de las ventas), pero los gastos SG&A aumentaron un 26% a 130,3 millones debido a la expansi贸n comercial de Axsome. I+D se mantuvo estable en 49,5 millones con varios programas CNS en etapas avanzadas en curso.
El efectivo y equivalentes cerraron en 303,0 millones; el consumo de efectivo operativo cay贸 a 75,8 millones. En mayo, la compa帽铆a refinanci贸 mediante una nueva l铆nea de 570 millones con Blackstone: un pr茅stamo a plazo de 120 millones y una l铆nea revolvente de 70 millones utilizada, cancelando el pr茅stamo m谩s costoso de Hercules y esperando reducir los gastos por intereses; Blackstone tambi茅n invirti贸 15 millones en acciones comunes. La deuda total ahora es de 188 millones, el patrimonio de los accionistas de 73 millones.
La FDA aprob贸 en enero de 2025 la terapia para migra帽a Symbravo, con lanzamiento en EE.UU. en junio, dando a Axsome tres productos comerciales. La direcci贸n considera que la liquidez actual financia las operaciones al menos por 12 meses. Los riesgos clave son la sostenida adopci贸n comercial, reembolsos/descuentos significativos acumulados (118 millones) y las p茅rdidas operativas continuas.
Q2-25 項る摐霛检澑: Auvelity, Sunosi 氚� Symbravo 於滌嫓 齑堦赴 欤缄皠鞐� 頌橃瀰鞏� 靾滊Г於� 1鞏� 5觳滊 雼煬(+72% 鞝勲厔 雽�牍�) 旮半; GAAP 靾滌啇鞁れ潃 4,800毵� 雼煬(-39% 鞝勲厔 雽�牍�) 霕愲姅 欤茧嫻 -0.97雼煬搿� 於曥唽霅�.
6臧滌洈 毵れ稖鞚� 2鞏� 7,150毵� 雼煬(+67%)鞐� 雼枅瓿� 靻愳嫟鞚� 1鞏� 740毵� 雼煬搿� 欷勳柎霌�. 齑濎澊鞚惦鞚� 雴掙矊 鞙犾(毵れ稖鞗愱皜 鞎� 9%) 霅橃棃鞙茧倶, Axsome鞚� 鞓侅梾 頇曥灔鞙茧 韺愲Г甏�毽箘(SG&A)電� 1鞏� 3,030毵� 雼煬搿� 26% 歃濌皜. 鞐瓣惮臧滊皽牍�(R&D)電� 4,950毵� 雼煬搿� 鞎堨爼鞝侅澊氅� 鞐煬 頉勱赴 欷戩稊鞁犼步瓿�(CNS) 頂勲攴鸽灗鞚� 歆勴枆 欷�.
順勱笀 氚� 順勱笀靹� 鞛愳偘鞚� 3鞏� 300毵� 雼煬搿� 毵堦皭; 鞓侅梾順勱笀 靻岆電� 7,580毵� 雼煬搿� 臧愳唽. 5鞗旍棎 Blackstone瓿� 5鞏� 7,000毵� 雼煬 攴滊鞚� 鞁犼窚 旮堨湹瓿勳暯鞚� 韱淀暣 鞛湹鞛�: 1鞏� 2,000毵� 雼煬鞚� 旮绊暅攵� 雽�於滉臣 7,000毵� 雼煬鞚� 毽臣牍� 雽�於� 靷毄, 雿� 牍勳毄鞚� 雴掛潃 Hercules 雽�於� 靸來櫂 氚� 鞚挫瀽 牍勳毄 鞝堦皭 旮半寑; Blackstone鞚� 氤错喌欤检棎 1,500毵� 雼煬霃� 韴瀽. 齑� 攵�毂勲姅 順勳灛 1鞏� 8,800毵� 雼煬, 欤检＜ 歆�攵勳潃 7,300毵� 雼煬.
FDA電� 2025雲� 1鞗旍棎 韼鸽憪韱� 旃橂鞝� Symbravo毳� 鞀轨澑頄堨溂氅�, 6鞗� 氙戈淡 於滌嫓搿� Axsome鞚� 3臧滌潣 靸侅梾 鞝滍拡鞚� 氤挫湢. 瓴届榿歆勳潃 順勳灛 鞙犽彊靹膘澊 斓滌唽 12臧滌洈臧� 鞖挫榿 鞛愱笀鞚� 歆�鞗愴暊 瓴冹溂搿� 氤搓碃 鞛堨潓. 欤检殧 鞙勴棙鞚� 歆�靻嶌爜鞚� 靸侅梾鞝� 靾橃殧, 靸侂嫻頃� 毽矤鞚错姼/頃犾澑(1鞏� 1,800毵� 雼煬 氚滌儩) 氚� 歆�靻嶌爜鞚� 鞖挫榿 靻愳嫟.
Titre Q2-25 : Chiffre d'affaires net de 150,0 M$ (+72% en glissement annuel) port茅 par Auvelity, Sunosi et les premi猫res semaines du lancement de Symbravo ; la perte nette selon les normes GAAP s'est r茅duite 脿 48,0 M$ (-39% en glissement annuel) soit -0,97 $/action.
Le chiffre d'affaires sur six mois a atteint 271,5 M$ (+67%) tandis que la perte a 茅t茅 r茅duite 脿 107,4 M$. La marge brute est rest茅e 茅lev茅e (co没t des ventes 鈮�9% des ventes), mais les frais SG&A ont augment茅 de 26% pour atteindre 130,3 M$ suite 脿 l'expansion commerciale d'Axsome. La R&D est rest茅e stable 脿 49,5 M$ avec plusieurs programmes CNS en phase avanc茅e en cours.
La tr茅sorerie et 茅quivalents s'茅l猫vent 脿 303,0 M$ ; la consommation de tr茅sorerie op茅rationnelle est tomb茅e 脿 75,8 M$. En mai, la soci茅t茅 a refinanc茅 via une nouvelle facilit茅 de 570 M$ avec Blackstone : un pr锚t 脿 terme de 120 M$ et une ligne de cr茅dit renouvelable de 70 M$ utilis茅e, remboursant le pr锚t plus co没teux Hercules et pr茅voyant une r茅duction des charges d'int茅r锚ts ; Blackstone a 茅galement investi 15 M$ en actions ordinaires. La dette totale est d茅sormais de 188 M$, les capitaux propres des actionnaires de 73 M$.
La FDA a approuv茅 en janvier 2025 la th茅rapie contre la migraine Symbravo, lanc茅e aux 脡tats-Unis en juin, portant 脿 trois le nombre de produits commerciaux d'Axsome. La direction estime que la liquidit茅 actuelle finance les op茅rations pour au moins 12 mois. Les principaux risques sont une adoption commerciale soutenue, des remises/ristournes importantes accumul茅es (118 M$) et des pertes op茅rationnelles continues.
Q2-25 脺berschrift: Nettoumsatz 150,0 Mio. $ (+72% im Jahresvergleich) getrieben von Auvelity, Sunosi und den ersten Wochen des Symbravo-Starts; GAAP-Nettogewinnr眉ckgang auf 48,0 Mio. $ (-39% im Jahresvergleich) bzw. 鈥�0,97 $/Aktie.
Sechsmonatsumsatz erreichte 271,5 Mio. $ (+67%), w盲hrend der Verlust auf 107,4 Mio. $ reduziert wurde. Bruttomarge blieb hoch (Kosten der Umsatzerl枚se 鈮�9% des Umsatzes), aber SG&A stiegen um 26% auf 130,3 Mio., da Axsome seine kommerzielle Pr盲senz ausbaute. F&E blieb mit 49,5 Mio. stabil, mehrere sp盲te CNS-Programme laufen.
Barmittel und 脛quivalente schlossen bei 303,0 Mio.; operativer Cashburn fiel auf 75,8 Mio. Im Mai refinanzierte das Unternehmen 眉ber eine neue 570-Mio.-$-Fazilit盲t mit Blackstone: 120 Mio. $ Terminkredit und 70 Mio. $ revolvierender Kredit gezogen, wodurch der teurere Hercules-Kredit abgel枚st und Zinskosten voraussichtlich gesenkt werden; Blackstone investierte zudem 15 Mio. $ in Stammaktien. Gesamtschulden nun 188 Mio., Eigenkapital der Aktion盲re 73 Mio.
Die FDA genehmigte im Januar 2025 die Migr盲netherapie Symbravo, Markteinf眉hrung in den USA im Juni, womit Axsome drei kommerzielle Produkte besitzt. Das Management geht davon aus, dass die aktuelle Liquidit盲t den Betrieb mindestens 12 Monate finanziert. Wesentliche Risiken sind nachhaltige Marktdurchdringung, betr盲chtliche R眉ckerstattungen/Rabatte (118 Mio. $ gebildet) und fortlaufende operative Verluste.
- Revenue surged 72% YoY to $150.0 M, reflecting robust uptake of Auvelity/Sunosi and initial Symbravo sales.
- Net loss narrowed 39% YoY to $48.0 M, improving EPS to 鈥�$0.97 from 鈥�$1.67.
- Blackstone $570 M financing refinanced higher-cost debt, expected to reduce interest expense and offers additional $250 M optional capital.
- Healthy liquidity of $303 M plus new facility supports 鈮�12-month operating runway.
- FDA approval & June launch of Symbravo adds a third revenue stream and diversifies the portfolio.
- Company remains unprofitable with operating loss of $36.7 M and accumulated deficit of $1.23 B.
- SG&A rose 26% YoY to $130.3 M, outpacing revenue growth and pressuring margins.
- Total debt increased to $188 M after new borrowings; leverage must be managed.
- High gross-to-net deductions with rebates/discounts liability climbing to $118 M, eroding realized pricing.
- Shareholders鈥� equity only $73 M, indicating a highly leveraged balance sheet relative to equity.
Insights
TL;DR: Strong top-line growth and lower cost debt extend runway, but profit inflection still unclear.
Revenue momentum is impressive鈥擜uvelity and Sunosi grew sharply and Symbravo adds a new lever. Gross margin held near 90%, evidencing product pricing power. The Blackstone facility replaces higher-rate Hercules debt, cutting the effective rate to SOFR+4.75% and deferring large amortization until 2030, a cash-flow win. Yet SG&A inflation outpaced sales (up 26% YoY) as the company ramps three brands, and total operating expenses still exceed revenue by >20%. Net leverage is ~0.3脳 sales, manageable but worth monitoring given future R&D and launch spend. Path to breakeven likely depends on accelerating Auvelity scripts and rapid Symbravo adoption.
TL;DR: Triple-product portfolio plus cheaper capital signal upside; execution risk remains.
Axsome now markets treatments for depression, sleep disorders and migraine鈥攖hree distinct, large markets. The 72% YoY revenue jump validates demand and diversifies cash flows. Refinancing with Blackstone frees incremental capital (up to $250 M undrawn) and included an equity buy, aligning lender incentives. Cash of $303 M covers >12 months of forecast burn even before optional draws. If Symbravo repeats Auvelity鈥檚 early trajectory, 2026 profitability is plausible. Investors should watch rebate pressure and ensure SG&A efficiencies emerge post-launch curve.
Titolo Q2-25: Ricavi netti di 150,0 milioni di dollari (+72% su base annua) trainati da Auvelity, Sunosi e dalle prime settimane del lancio di Symbravo; la perdita netta GAAP si 猫 ridotta a 48,0 milioni di dollari (-39% su base annua) ovvero -0,97 dollari per azione.
I ricavi semestrali hanno raggiunto 271,5 milioni di dollari (+67%) mentre la perdita si 猫 ridotta a 107,4 milioni. Il margine lordo 猫 rimasto elevato (costo del venduto 鈮�9% delle vendite), ma le spese SG&A sono aumentate del 26% a 130,3 milioni, in seguito all'espansione della presenza commerciale di Axsome. La R&S 猫 rimasta stabile a 49,5 milioni con diversi programmi CNS in fase avanzata in corso.
La liquidit脿 e equivalenti si sono attestati a 303,0 milioni; il consumo di cassa operativo 猫 sceso a 75,8 milioni. A maggio la societ脿 ha rifinanziato tramite una nuova linea da 570 milioni con Blackstone: un prestito a termine da 120 milioni e una linea revolving da 70 milioni utilizzata, estinguendo il pi霉 costoso prestito Hercules e prevedendo una riduzione delle spese per interessi; Blackstone ha inoltre investito 15 milioni in azioni ordinarie. Il debito totale 猫 ora di 188 milioni, il patrimonio netto degli azionisti di 73 milioni.
La FDA ha approvato a gennaio 2025 la terapia per l'emicrania Symbravo, con lancio negli Stati Uniti a giugno, portando a tre i prodotti commerciali di Axsome. La direzione ritiene che la liquidit脿 attuale copra le operazioni per almeno 12 mesi. I rischi principali sono il mantenimento delle vendite commerciali, significativi rimborsi/sconti accumulati (118 milioni) e le perdite operative in corso.
Titular Q2-25: Ingresos netos de 150,0 millones de d贸lares (+72% interanual) impulsados por Auvelity, Sunosi y las primeras semanas del lanzamiento de Symbravo; la p茅rdida neta GAAP se redujo a 48,0 millones de d贸lares (-39% interanual) o -0,97 d贸lares por acci贸n.
Los ingresos a seis meses alcanzaron 271,5 millones (+67%), mientras que la p茅rdida se redujo a 107,4 millones. El margen bruto se mantuvo alto (costo de ventas 鈮�9% de las ventas), pero los gastos SG&A aumentaron un 26% a 130,3 millones debido a la expansi贸n comercial de Axsome. I+D se mantuvo estable en 49,5 millones con varios programas CNS en etapas avanzadas en curso.
El efectivo y equivalentes cerraron en 303,0 millones; el consumo de efectivo operativo cay贸 a 75,8 millones. En mayo, la compa帽铆a refinanci贸 mediante una nueva l铆nea de 570 millones con Blackstone: un pr茅stamo a plazo de 120 millones y una l铆nea revolvente de 70 millones utilizada, cancelando el pr茅stamo m谩s costoso de Hercules y esperando reducir los gastos por intereses; Blackstone tambi茅n invirti贸 15 millones en acciones comunes. La deuda total ahora es de 188 millones, el patrimonio de los accionistas de 73 millones.
La FDA aprob贸 en enero de 2025 la terapia para migra帽a Symbravo, con lanzamiento en EE.UU. en junio, dando a Axsome tres productos comerciales. La direcci贸n considera que la liquidez actual financia las operaciones al menos por 12 meses. Los riesgos clave son la sostenida adopci贸n comercial, reembolsos/descuentos significativos acumulados (118 millones) y las p茅rdidas operativas continuas.
Q2-25 項る摐霛检澑: Auvelity, Sunosi 氚� Symbravo 於滌嫓 齑堦赴 欤缄皠鞐� 頌橃瀰鞏� 靾滊Г於� 1鞏� 5觳滊 雼煬(+72% 鞝勲厔 雽�牍�) 旮半; GAAP 靾滌啇鞁れ潃 4,800毵� 雼煬(-39% 鞝勲厔 雽�牍�) 霕愲姅 欤茧嫻 -0.97雼煬搿� 於曥唽霅�.
6臧滌洈 毵れ稖鞚� 2鞏� 7,150毵� 雼煬(+67%)鞐� 雼枅瓿� 靻愳嫟鞚� 1鞏� 740毵� 雼煬搿� 欷勳柎霌�. 齑濎澊鞚惦鞚� 雴掙矊 鞙犾(毵れ稖鞗愱皜 鞎� 9%) 霅橃棃鞙茧倶, Axsome鞚� 鞓侅梾 頇曥灔鞙茧 韺愲Г甏�毽箘(SG&A)電� 1鞏� 3,030毵� 雼煬搿� 26% 歃濌皜. 鞐瓣惮臧滊皽牍�(R&D)電� 4,950毵� 雼煬搿� 鞎堨爼鞝侅澊氅� 鞐煬 頉勱赴 欷戩稊鞁犼步瓿�(CNS) 頂勲攴鸽灗鞚� 歆勴枆 欷�.
順勱笀 氚� 順勱笀靹� 鞛愳偘鞚� 3鞏� 300毵� 雼煬搿� 毵堦皭; 鞓侅梾順勱笀 靻岆電� 7,580毵� 雼煬搿� 臧愳唽. 5鞗旍棎 Blackstone瓿� 5鞏� 7,000毵� 雼煬 攴滊鞚� 鞁犼窚 旮堨湹瓿勳暯鞚� 韱淀暣 鞛湹鞛�: 1鞏� 2,000毵� 雼煬鞚� 旮绊暅攵� 雽�於滉臣 7,000毵� 雼煬鞚� 毽臣牍� 雽�於� 靷毄, 雿� 牍勳毄鞚� 雴掛潃 Hercules 雽�於� 靸來櫂 氚� 鞚挫瀽 牍勳毄 鞝堦皭 旮半寑; Blackstone鞚� 氤错喌欤检棎 1,500毵� 雼煬霃� 韴瀽. 齑� 攵�毂勲姅 順勳灛 1鞏� 8,800毵� 雼煬, 欤检＜ 歆�攵勳潃 7,300毵� 雼煬.
FDA電� 2025雲� 1鞗旍棎 韼鸽憪韱� 旃橂鞝� Symbravo毳� 鞀轨澑頄堨溂氅�, 6鞗� 氙戈淡 於滌嫓搿� Axsome鞚� 3臧滌潣 靸侅梾 鞝滍拡鞚� 氤挫湢. 瓴届榿歆勳潃 順勳灛 鞙犽彊靹膘澊 斓滌唽 12臧滌洈臧� 鞖挫榿 鞛愱笀鞚� 歆�鞗愴暊 瓴冹溂搿� 氤搓碃 鞛堨潓. 欤检殧 鞙勴棙鞚� 歆�靻嶌爜鞚� 靸侅梾鞝� 靾橃殧, 靸侂嫻頃� 毽矤鞚错姼/頃犾澑(1鞏� 1,800毵� 雼煬 氚滌儩) 氚� 歆�靻嶌爜鞚� 鞖挫榿 靻愳嫟.
Titre Q2-25 : Chiffre d'affaires net de 150,0 M$ (+72% en glissement annuel) port茅 par Auvelity, Sunosi et les premi猫res semaines du lancement de Symbravo ; la perte nette selon les normes GAAP s'est r茅duite 脿 48,0 M$ (-39% en glissement annuel) soit -0,97 $/action.
Le chiffre d'affaires sur six mois a atteint 271,5 M$ (+67%) tandis que la perte a 茅t茅 r茅duite 脿 107,4 M$. La marge brute est rest茅e 茅lev茅e (co没t des ventes 鈮�9% des ventes), mais les frais SG&A ont augment茅 de 26% pour atteindre 130,3 M$ suite 脿 l'expansion commerciale d'Axsome. La R&D est rest茅e stable 脿 49,5 M$ avec plusieurs programmes CNS en phase avanc茅e en cours.
La tr茅sorerie et 茅quivalents s'茅l猫vent 脿 303,0 M$ ; la consommation de tr茅sorerie op茅rationnelle est tomb茅e 脿 75,8 M$. En mai, la soci茅t茅 a refinanc茅 via une nouvelle facilit茅 de 570 M$ avec Blackstone : un pr锚t 脿 terme de 120 M$ et une ligne de cr茅dit renouvelable de 70 M$ utilis茅e, remboursant le pr锚t plus co没teux Hercules et pr茅voyant une r茅duction des charges d'int茅r锚ts ; Blackstone a 茅galement investi 15 M$ en actions ordinaires. La dette totale est d茅sormais de 188 M$, les capitaux propres des actionnaires de 73 M$.
La FDA a approuv茅 en janvier 2025 la th茅rapie contre la migraine Symbravo, lanc茅e aux 脡tats-Unis en juin, portant 脿 trois le nombre de produits commerciaux d'Axsome. La direction estime que la liquidit茅 actuelle finance les op茅rations pour au moins 12 mois. Les principaux risques sont une adoption commerciale soutenue, des remises/ristournes importantes accumul茅es (118 M$) et des pertes op茅rationnelles continues.
Q2-25 脺berschrift: Nettoumsatz 150,0 Mio. $ (+72% im Jahresvergleich) getrieben von Auvelity, Sunosi und den ersten Wochen des Symbravo-Starts; GAAP-Nettogewinnr眉ckgang auf 48,0 Mio. $ (-39% im Jahresvergleich) bzw. 鈥�0,97 $/Aktie.
Sechsmonatsumsatz erreichte 271,5 Mio. $ (+67%), w盲hrend der Verlust auf 107,4 Mio. $ reduziert wurde. Bruttomarge blieb hoch (Kosten der Umsatzerl枚se 鈮�9% des Umsatzes), aber SG&A stiegen um 26% auf 130,3 Mio., da Axsome seine kommerzielle Pr盲senz ausbaute. F&E blieb mit 49,5 Mio. stabil, mehrere sp盲te CNS-Programme laufen.
Barmittel und 脛quivalente schlossen bei 303,0 Mio.; operativer Cashburn fiel auf 75,8 Mio. Im Mai refinanzierte das Unternehmen 眉ber eine neue 570-Mio.-$-Fazilit盲t mit Blackstone: 120 Mio. $ Terminkredit und 70 Mio. $ revolvierender Kredit gezogen, wodurch der teurere Hercules-Kredit abgel枚st und Zinskosten voraussichtlich gesenkt werden; Blackstone investierte zudem 15 Mio. $ in Stammaktien. Gesamtschulden nun 188 Mio., Eigenkapital der Aktion盲re 73 Mio.
Die FDA genehmigte im Januar 2025 die Migr盲netherapie Symbravo, Markteinf眉hrung in den USA im Juni, womit Axsome drei kommerzielle Produkte besitzt. Das Management geht davon aus, dass die aktuelle Liquidit盲t den Betrieb mindestens 12 Monate finanziert. Wesentliche Risiken sind nachhaltige Marktdurchdringung, betr盲chtliche R眉ckerstattungen/Rabatte (118 Mio. $ gebildet) und fortlaufende operative Verluste.
FORM | S-8 | ||||||||||
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
(Exact name of Registrant as Specified in its Charter)
| Delaware | 77-0142404 | |||||||
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification Number) | |||||||
(Address of principal executive offices) | ||
(Registrant's telephone number, including area code) | ||
Secretary and Chief Legal Officer
8x8, Inc.
| Large accelerated filer | ☐ | Accelerated filer | ☒ | |||||||||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ☒ | |||||||||||||||||
| Emerging growth company | ☐ | |||||||||||||||||||
Signature | Title | Date | ||||||
/s/ Samuel Wilson Samuel Wilson | Chief Executive Officer and Director (Principal Executive Officer and Director) | August 4, 2025 | ||||||
/s/ Kevin Kraus Kevin Kraus | Chief Financial Officer (Principal Financial Officer) | August 4, 2025 | ||||||
/s/ Jaswinder Pal Singh Jaswinder Pal Singh | Chairman and Director | August 4, 2025 | ||||||
/s/ Monique Bonner Monique Bonner | Director | August 4, 2025 | ||||||
/s/ Andrew Burton Andrew Burton | Director | August 4, 2025 | ||||||
/s/ Todd Ford Todd Ford | Director | August 4, 2025 | ||||||
/s/ Alison Gleeson Alison Gleeson | Director | August 4, 2025 | ||||||
/s/ John Pagliuca John Pagliuca | Director | August 4, 2025 | ||||||
/s/ Elizabeth Theophille Elizabeth Theophille | Director | August 4, 2025 | ||||||
Source:
FAQ
What were Axsome Therapeutics' (AXSM) Q2 2025 revenues?
Did AXSM reduce its net loss in Q2 2025?
How much cash does Axsome have and how long will it last?
What are the key terms of the May 2025 Blackstone loan agreement?
When was Symbravo approved and launched?
How many AXSM shares were outstanding?
What is Axsome's current debt level?
